Innovative Cardiovascular Solutions

Innovative Cardiovascular Solutions is a clinical-stage medical device company developing the Emblok 360° embolic protection system. The device is designed to capture particulate debris during transcatheter aortic valve replacement (TAVR) and other left-heart procedures to protect the brain, heart, kidneys, and intestines from embolic injury, thereby aiming to reduce stroke risk and other major complications. The company is led by an experienced executive team and supported by a prominent scientific advisory board of interventional cardiologists. It is positioned in the high-growth structural heart market but faces significant competition and the need to demonstrate clinical and economic value to achieve adoption.

The Emblok 360° is a single-use medical device designed for whole-body embolic protection during transcatheter left-heart procedures. It is engineered to deploy in the aorta to block and capture embolic debris (calcific plaque, thrombus) before it can travel to the brain, heart, kidneys, and intestines, aiming to reduce procedure-related strokes and other complications.

The embolic protection market is dominated by cerebral protection devices like Boston Scientific's Sentinel Cerebral Protection System and Edwards Lifesciences' TriGuard 3. Emblok 360° competes by claiming broader, whole-body protection. Other competitors include embolic filters in development and alternative technologies. The key battleground is clinical evidence proving superior reduction in composite clinical outcomes.